| Popis: |
Background: Universal tumor screening (UTS) for Lynch syndrome (LS) on all colorectal (CRC) and endometrial cancers (EC) is recommended by multiple professional societies. In 2012, it was reported that UTS is not uniformly performed, only occurring in 15% of Community Hospital Cancer Programs (CCPs), 36% of College of Surgeons-Accredited Community Hospital Comprehensive Cancer Programs (COMPs), and 71% of National Cancer Institute–Comprehensive Cancer Centers (NCI-CCCs). Another study performed in 2018 by Hissong et al. found that 86% of institutions surveyed were performing UTS for LS in CRC patients. Our aims were to ascertain what percentage of hospitals were performing UTS for LS in 2021, and to assess if there was a difference in UTS rates between CRC and EC.Methods: All 51 NCI-CCCs and 100 randomly selected CCPs and COMPs were asked to complete a 23-question survey on REDCAP assessing their UTS protocol for CRC, EC, and other LS-associated cancers. Genetic counselors, tumor registrars, or pathologists completed the survey. Results: 74 survey responses were received, for an overall response rate of 29.5% [46/51 (90%) of NCI-CCCs, 16/100 (16%) of COMPs, and 12/100 (12%) of CCPs)]. 85.1% (63) performed UTS in all patients with CRC as follows: 89% of NCI-CCCs, 81% of COMPs, and 75% of CCPs. Rates of UTS for CRC patients did not significantly differ based on the type of cancer program (P = .41789). In addition, 68% (n=57) of respondents performed UTS in all patients with EC, including 80% of NCI-CCCs, 50% of COMPs, and 50% of CCPs While it was not statistically significant (P = .059997), our data suggests that UTS rates for EC were higher among NCI-CCCs than COMPs or CCPs. UTS for Lynch syndrome is significantly (P = 0.00937) more often performed for CRC than for EC patients. Comparing UTS for LS in CRC patients to past studies, there was a statistically significant increase from Beamer et al. (2012) (P |
